<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280927</url>
  </required_header>
  <id_info>
    <org_study_id>JBL_OM_IV</org_study_id>
    <nct_id>NCT03280927</nct_id>
  </id_info>
  <brief_title>Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis</brief_title>
  <official_title>A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antifungal efficacy and safety of Jublia® topical solution will be assessed through an
      administration for 48 weeks to patients diagnosed with a mild or moderate onychomycosis due
      to dermatophyte.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate anti-fungal activity and safety of efinaconazole in patients with mild to moderate
      toenail onychomycosis caused by dermatophytes that received a 48-week administration of
      efinaconazole.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completely cured subjects</measure>
    <time_frame>52 weeks</time_frame>
    <description>The ratio of completely cured subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete or almost complete cure rates</measure>
    <time_frame>52 weeks</time_frame>
    <description>The ratio of subjects showing less than 5% of infection area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycologic cure rates</measure>
    <time_frame>52 weeks</time_frame>
    <description>Negative results from both the KOH Direct Microscopic Inspection and Fungi Cultivation Inspection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy rates</measure>
    <time_frame>52 weeks</time_frame>
    <description>The ratio of subjects affected target nail area less than 10%</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mild to Moderate Onychomycosis Due to Dermatophyte</condition>
  <arm_group>
    <arm_group_label>Jublia®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jublia®</intervention_name>
    <description>Jublia® topical solution</description>
    <arm_group_label>Jublia®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female subjects of ages in the range over 19.

          -  The subjects diagnosed with onychomycosis in up to 6 toenails at least

             1 great toenail woth no fingernails

          -  The subjects diagnosed with a mild to moderate onychomycosis (20% to 50% of surface of
             target nail without nail matrix infection or dermatophytoma)

          -  The subjects having target nails less than 3mm in thickness and over 3mm in length

          -  Positive indication on KOH Direct Microscopic Inspection on target nail

          -  Positive dermatophyte or dermatophyte/candida on Fungi Cultivation Inspection on
             target nail

          -  The subjects completely understood the clinical trial through detailed explanation
             presented, determined to participate in the clinical trial spontaneously, and agreed
             to observe precautions suggested thereby through written consent.

        Exclusion Criteria:

          -  The subjects suffering other diseases that may cause nail abnormalities or are
             supposed to be affecting the assessment of the efficacy of study agent by the judgment
             of investigators

          -  The subjects having a case history of hypersensitivity reaction to the component of
             Jublia® topical solution or Azole derivatives.

          -  The pregnant, lactating, or fertile woman free from pertinent contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lee Yang-Won, Ph.D</last_name>
    <phone>02-2030-7573</phone>
    <email>20050078@kuh.ac.kr</email>
  </overall_contact>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efinaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

